Dermira Ends UCB Cimzia Psoriasis Pact To Focus On Its Own Pipeline

As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.

Skin condition
Demira Ends UCB Cimza Psoriasis Pact To Focus On Own Dermatology • Source: Shutterstock

Dermira Inc. is ending its partnership with UCB SA developing the Belgian company's biologic Cimzia (certolizumab pegol) in the US, EU and Canada for the treatment of psoriasis to fully focus on its own dermatological assets, two of which are in pivotal Phase III trials.

‍Dermira in-licensed Cimzia, a marketed rheumatoid arthritis drug, from UCB in 2014 which Dermira has been developing for plaque psoriasis,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.